Investor Profile: Novartis Venture Fund — Thesis, Cheque Size & How to Apply

The Novartis Venture Fund (NVF) is the corporate venture arm of Swiss pharmaceutical giant Novartis, and it has been backing life-science startups since 1996. Run from Basel and Cambridge, Massachusetts, it is one of the longest-lived pharma venture funds in the world — and one of the most focused: it invests only in novel therapeutics and platforms, with a hands-on, board-level style.

Thesis: novel science for unmet medical need

NVF's overriding ambition is to address unmet patient needs while delivering significant returns. It looks for novel proprietary science with a clear mechanism, strong management and board experience, and capital efficiency. Its primary mandate is to optimise financial returns by backing paradigm-changing products in areas of high unmet need.

Its current site is explicit: while it works with biotech and biopharma companies developing novel therapeutics and platforms, it does not invest in medtech or diagnostics. Founders in devices or diagnostics should not pitch NVF, however strong their technology.

Fund size and cheque size

NVF manages approximately $750 million in committed capital across more than 40 portfolio companies in North America and Europe. It does not publish a fixed cheque range on its current site, but its strategy is built around larger, focused investments: it typically leads or co-leads a round and takes a board seat, staying involved from early development through to later stages. Older profiles of the fund describe total investments of up to $30 million per company over its life, which fits its pattern of concentrating capital rather than spraying it.

Notable portfolio

NVF's recent record shows its taste for hard, differentiated science. Artios Pharma, a Cambridge-based company targeting the DNA damage response in cancer, closed an oversubscribed €99 million ($115 million) Series D with NVF among its backers, funding its DNA-damage-response cancer programmes. Epsilogen, a London company developing novel immunoglobulin antibodies for cancer, raised a £30.75 million ($41.20 million) Series B led by NVF. Inflazome closed a $17 million Series A from NVF and Fountain Healthcare Partners to develop treatments for chronic inflammatory diseases. FORE Biotherapeutics raised a $67.4 million Series D-2 extension to advance its BRAF cancer therapy, again with NVF involved.

Partners and programmes

NVF's team is split between Basel and Cambridge, staffed by people with deep drug-development backgrounds. It runs no accelerator and offers no credits or perks programme; its value-add is board-level partnership, scientific diligence, and access to Novartis's research and development expertise. Since 1996, the fund says it has helped create more than 1,000 jobs across its portfolio.

How to apply for funding from Novartis Venture Fund

NVF's published process starts with non-confidential information: the company, the team, the technology and data, the financials and the exit plan. Founders should therefore lead with a crisp, non-confidential deck that makes the unmet need, mechanism of action and clinical impact immediately legible, approaching via nvfund.com or a warm introduction from a life-science investor. Confidential presentations follow only after that first screen — so do not open with a data room, and do not pitch medtech or diagnostics.